Next-Generation Sequencing Services Market Size, Growth, Trends | Report 2022-2030
The global next-generation sequencing services market size was accounted at USD 1.2 billion in 2021 and it is expected to surpass around USD 4.65 billion by 2030, growing at a CAGR of 18.5% from 2022 to 2030.
The development of next-generation sequencing (NGS) technologies has revolutionized gene sequencing in terms of reproducibility and cost savings. This has resulted in the introduction of several advancements in NGS technology to promote its usage in clinical labs and hospitals. Most current innovations in this field revolve around simplifying the usage of seq-technology and making it more sophisticated. These factors have driven the uptake of NGS services across various end-users.
Next-generation sequencing has progressed from research to clinical use in the last five years. Around 14 nations have launched large-scale genome sequencing programs, with nearly 60 million people expected to have their genome analyzed by 2025. Conventional disease testing service providers have broadened their portfolio with a rising trend of seq-based genetic tests. For instance, ARUP Laboratories announced the release of new coronavirus tests in March 2022, and IDbyDNA, Inc. partnered with another firm to introduce new coronavirus tests, an NGS test for respiratory illnesses, to aid physicians in evaluating patients with pneumonia and some other respiratory problems.
With the rising trend of high throughput sequencing within the pharma and biotech industry, there is a need for more developments to improve the speed and convenience of high throughput seq-platforms and simplify workflows. As a result, companies are focusing on the development of solutions to simplify the amplification and purification of samples and starting input. In March 2022, Illumina, Inc. announced the release of TruSigh Oncology (TSO) Comprehensive (EU), a comprehensive diagnostic that evaluates several tumor genes and indicators to identify a patient's cancer's individual molecular profile. The in vitro diagnostic (IVD) kit would assist in influencing genomic decisions for patients with cancer across Europe, with its global debut taking place first in Europe.
Scope of the Report
| Report Coverage | Details |
| Market Size in 2021 | USD 1.2 Billion |
| Revenue Forecast By 2030 | USD 4.65 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 18.5% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Companies Mentioned | Illumina, Inc.; Veritas Genetics; BGI; GENEWIZ Germany GmbH; ABM Inc.; ARUP Laboratories; Novogene Corporation; Lucigen; Quest Diagnostics; Gene by Gene |
Service Type Insights
Human genome sequencing held the largest revenue share of over 30.0% in 2021. It is the most widely offered and practiced segment. The presence of a substantial number of key players in this segment is contributing to the segment's growth. Companies operating in this segment include BGI-Complete Genomics, Veritas Genetics, Macrogen, Full genomes.com, Novogene, SureGenomics, Partners LMM, Genos, BGI, 14 labs, Gene-by-Gene, and Personalis.
Gene regulation services are estimated to exhibit a lucrative CAGR during the forecast period. It covers small RNA sequencing, ChIP sequencing, lncRNA seq, isoform sequencing, and bisulfite sequencing. Various advantages offered by RNA sequencing have enabled the replacement of microarrays in many applications. It is expected that the application of RNA-seq will continue to expand over the coming years, thus driving the segment at a rapid pace.
Workflow Insights
The sequencing segment accounted for the largest revenue share of over 50.0% in 2021 owing to the high cost of instruments. Companies have been offering a broad portfolio for a wide spectrum of sample types. For example, Novogene Corporation conducts sequencing and generates publication-ready data for the success of research programs of customers from various domains such as agricultural, biomedical, and environmental science.
NGS services offered in the market include various aspects of sequencing, ranging from consultation to final result derivation. Some companies offer thorough protocol while others are engaged in offering standalone services to customers that have a lab equipped with NGS facilities but seek to outsource some portions of NGS workflow.
Analysis of NGS data poses great challenges for researchers engaged in conducting sequencing protocols for their projects. This is because a systematic and intelligent methodology is required for efficient processing and interpretation of data. As there is an increase in the number of sequenced reads per run, the subsequent growth in demand for robust data management solutions is projected.
End-use Insights
Universities and other research entities held the largest revenue share of over 50.0% in 2021 owing to the fact that NGS is primarily being used for research purposes. Research entities are utilizing sequencing services to improve the outcomes of their projects and gain in-depth insights into the mechanism of disease occurrence.
However, with the rising trend of clinical NGS, hospitals, and clinics are projected to witness the fastest growth over the forecast period. This trend in clinical settings is marked by the growing implementation of NGS technology for the detection of fetal aneuploidies through analyzing fetal cfDNA obtained from a single maternal blood draw in prenatal diagnostic procedures.
In addition to this, the liquid biopsy NGS panel is receiving great attention among healthcare entities, including clinics and hospitals, for cancer management. The definition of a proper regulatory framework for the use of NGS in clinical settings is expected to support the projected growth.
Regional Insights
North America accounted for the largest revenue share of over 45.0% in 2021 owing to factors such as a well-established informatics network, effective regulatory guidelines pertaining to approval and usage of genetic tests, and the presence of market leaders in the region. In addition, the growing number of FDA-approved genomic tests in the U.S. is anticipated to drive the regional market throughout the forecast period.
The Asia Pacific market is expected to serve as a lucrative source of revenue over the forecast period. The growing attention of government bodies toward the maintenance of public health and consequent investments in the development of advanced diagnostic approaches are anticipated to spur the uptake of seq-services in the region.
Furthermore, domestic players in Asian countries are involved in forming mutually beneficial partnerships among each other as well as with global companies for the establishment of NGS service providers. For instance, in November 2021, Novogene stated during the 44th Annual Gathering of Molecular Biological Society of Japan (MSBJ) in Japan that they will be launching single-cell sequencing services specifically for their Japanese customers. Novogene Japan K.K. will provide on-site service to assist clients in optimizing their single-cell planning with this new service. It gives researchers the freedom to enjoy a dependable and seamless end-to-end sequencing solution for their single-cell research, starting with research design projects, cell barcoding, library creation, sequencing, and bioinformatic analysis.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and End-use Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Next-Generation Sequencing Services Market
5.1. COVID-19 Landscape: Flow Computers Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Next-Generation Sequencing Services Market, By Service Type
8.1. Next-Generation Sequencing Services Market, by Service Type Type, 2022-2030
8.1.1. Human Genome Sequencing
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Single Cell Sequencing
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Microbial Genome-based Sequencing
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Gene Regulation Services
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Small RNA Sequencing
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. ChIP Sequencing
8.1.6.1. Market Revenue and Forecast (2017-2030)
8.1.7. Other Gene Regulation-based Services
8.1.7.1. Market Revenue and Forecast (2017-2030)
8.1.8. Animal & Plant Sequencing
8.1.8.1. Market Revenue and Forecast (2017-2030)
8.1.9. Other Sequencing Services
8.1.9.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Next-Generation Sequencing Services Market, By Workflow
9.1. Next-Generation Sequencing Services Market, by Workflow, 2022-2030
9.1.1. Pre-sequencing
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Sequencing
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Data Analysis
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Next-Generation Sequencing Services Market, By End-use Channel
10.1. Next-Generation Sequencing Services Market, by End-use Channel, 2022-2030
10.1.1. Universities & Other Research Entities
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Hospitals & Clinics
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Pharma & Biotech Entities
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Next-Generation Sequencing Services Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Service Type (2017-2030)
11.1.2. Market Revenue and Forecast, by Workflow (2017-2030)
11.1.3. Market Revenue and Forecast, by End-use Channel (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Service Type (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Workflow (2017-2030)
11.1.4.3. Market Revenue and Forecast, by End-use Channel (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Service Type (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Workflow (2017-2030)
11.1.5.3. Market Revenue and Forecast, by End-use Channel (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Service Type (2017-2030)
11.2.2. Market Revenue and Forecast, by Workflow (2017-2030)
11.2.3. Market Revenue and Forecast, by End-use Channel (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Service Type (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Workflow (2017-2030)
11.2.4.3. Market Revenue and Forecast, by End-use Channel (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Service Type (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Workflow (2017-2030)
11.2.5.3. Market Revenue and Forecast, by End-use Channel (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Service Type (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Workflow (2017-2030)
11.2.6.3. Market Revenue and Forecast, by End-use Channel (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Service Type (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Workflow (2017-2030)
11.2.7.3. Market Revenue and Forecast, by End-use Channel (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Service Type (2017-2030)
11.3.2. Market Revenue and Forecast, by Workflow (2017-2030)
11.3.3. Market Revenue and Forecast, by End-use Channel (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Service Type (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Workflow (2017-2030)
11.3.4.3. Market Revenue and Forecast, by End-use Channel (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Service Type (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Workflow (2017-2030)
11.3.5.3. Market Revenue and Forecast, by End-use Channel (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Service Type (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Workflow (2017-2030)
11.3.6.3. Market Revenue and Forecast, by End-use Channel (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Service Type (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Workflow (2017-2030)
11.3.7.3. Market Revenue and Forecast, by End-use Channel (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Service Type (2017-2030)
11.4.2. Market Revenue and Forecast, by Workflow (2017-2030)
11.4.3. Market Revenue and Forecast, by End-use Channel (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Service Type (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Workflow (2017-2030)
11.4.4.3. Market Revenue and Forecast, by End-use Channel (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Service Type (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Workflow (2017-2030)
11.4.5.3. Market Revenue and Forecast, by End-use Channel (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Service Type (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Workflow (2017-2030)
11.4.6.3. Market Revenue and Forecast, by End-use Channel (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Service Type (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Workflow (2017-2030)
11.4.7.3. Market Revenue and Forecast, by End-use Channel (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Service Type (2017-2030)
11.5.2. Market Revenue and Forecast, by Workflow (2017-2030)
11.5.3. Market Revenue and Forecast, by End-use Channel (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Service Type (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Workflow (2017-2030)
11.5.4.3. Market Revenue and Forecast, by End-use Channel (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Service Type (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Workflow (2017-2030)
11.5.5.3. Market Revenue and Forecast, by End-use Channel (2017-2030)
Chapter 12. Company Profiles
12.1. Illumina, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Veritas Genetics
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. BGI
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. GENEWIZ Germany GmbH
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. ABM Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. ARUP Laboratories
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Novogene Corporation
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Lucigen
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Quest Diagnostics
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Gene by Gene
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers